Press Releases

  1. Home
  2. Press Releases

Health Canada Endorses Lophophora Williamsii, Elevating Lophos Holdings Inc. as a Leader in Natural Health Innovation

by in Press Releases January 23, 2024

Napanee, Ontario, January 23, 2024 – Lophos Holdings Inc. (“Lophos”) (CSE:MESC), a trailblazerin the production of Lophophora williamsii (peyote), proudly announces a significant stride inthe natural health sector. Health Canada’s recent recognition of Lophophora williamsii as aNatural Health Product ingredient marks a pivotal moment in the therapeutic use ofpsychoactive plants, reinforcing Lophos’ position at the […]

read more

Lophos Secures Game-Changing Controlled Substance Dealer’s License with the Expertise of Canalytica Corp.

by in Press Releases October 10, 2023

NAPANEE, Ontario, Oct. 10, 2023 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos“, or the “Company“) (CSE:MESC) is delighted to share additional information on its wholly-owned subsidiary, Lophos Pharmaceuticals Corp., which has achieved a significant milestone by obtaining a Controlled Substance Dealer’s License from Health Canada for their facility located in Napanee, Ontario. Facility Overview Permitted […]

read more

Lophos Opens Early Enrollment for Peyote Sales and Appoints Market Maker

by in Press Releases September 19, 2023

VANCOUVER, British Columbia, Sept. 19, 2023 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos“, or the “Company“) (CSE:MESC) is delighted to share a substantial milestone. Its wholly owned subsidiary, Lophos Pharmaceuticals Corp., has initiated the early enrollment phase for acquiring peyote cactus (Lophophora williamsi) via its official website, http://www.lophos.com. Interested parties can now register with Lophos […]

read more

Lophos Pharmaceuticals Receives Controlled Substances Dealers License (CSDL) From Health Canada

by in Press Releases August 25, 2023

NAPANEE, Ontario, Aug. 25, 2023 (GLOBE NEWSWIRE) — Lophos Holdings Inc. is pleased to announce that its wholly owned subsidiary, Lophos Pharmaceuticals Corp., has received its Controlled Substances Dealers License (CSDL) from Health Canada, effective as of August 23, 2023. The Controlled Substances Dealers License (CSDL) permits Lophos Pharmaceuticals to possess, produce, sell/provide, send, transport […]

read more

Canadian Psychedelic Research Company Lophos Pharmaceuticals Inc. Engages KGK Science for Novel Peyote Study

by in Press Releases February 14, 2023

Toronto, Ontario–(Newsfile Corp. – March 21, 2022) – Lophos Pharmaceuticals Inc., a Canadian psychedelic research company focused on cultivation and drug development, engages KGK Science Inc. to evaluate a path to market for sustainably-grown peyote-derived natural health products (NHPs). Peyote has legal status in Canada, but mescaline – the drug derived from the plant – remains a […]

read more

Lophos Pharmaceuticals Corp. Announces Participation in the Benzinga Psychedelics Capital Conference

by in Press Releases February 14, 2023

Napanee, Ontario–(Newsfile Corp. – April 12, 2022) – Lophos Pharmaceuticals Corp. , a biosciences research and development company, will be participating in the Benzinga Psychedelics Capital Conference, which will take place on April 19 at the Fontainebleau Miami Beach. Claire Stawnyczy, CEO will be speaking at 01:00 PM ET on April 19th. Interested parties can register to attend here. Members of […]

read more

Psychedelic Research Company LophosPharmaceuticals Corp. Developing Sustainably-Grown Peyote in Canada

by in Press Releases February 14, 2023

Toronto, Ontario–(Newsfile Corp. – April 28, 2022) – Lophos Pharmaceuticals Corp., Lophos is a Canadian psychedelic research company focused on peyote and its derivatives such as mescaline. Peyote, an endangered plant species with a long history of therapeutic use has legal status in Canada, but mescaline, a powerful psychedelic molecule derived from the plant, remains a Schedule 3 controlled […]

read more

Peyote Research Company – LophosPharmaceuticals Corp. Presenting at Lift & Co Expo in Toronto

by in Press Releases February 14, 2023

Toronto, Ontario–(Newsfile Corp. – May 10, 2022) – Lophos Pharmaceuticals Corp., a Canadian psychedelic research company is scheduled to present at the upcoming Lift & Co. Expo next week, Friday, May 13th. The feature presentation titled,  “Nature’s Medicine: Peyote’s Place in the Psychedelic Industry,” is scheduled for 11:30am. Claire Stawnyczy, President & CEO of Lophos Pharma, will present her plan […]

read more

Lophos Pharma: Exploring the Potential of Mescaline

by in Press Releases February 24, 2022

Lophos Pharma is a Canadian peyote-focused psychedelics company. It was co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s potential in a range of indications, optimize the cultivation of peyote, and preserve the plant. It’s an ambitious plan in an emerging sector that has so far embraced the possibilities of compounds such […]

read more

    We specialize in plant-based psychedelic research and cultivation, and we support the traditional use of psychedelic medicines.

    We endeavor to provide safe access to plant-based therapeutics and to discover and develop new pharmachological treatments for disorders that may find relief in psychedelic based therapies.

    EMAIL (GENERAL INQUIRY)

    info@lophos.com

    EMAIL (INVESTOR INQUIRY)

    investors@lophos.com